Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
NCT05685602Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Jun 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emavusertib in pancreatic ductal adenocarcinoma (PDAC), sponsored by National Cancer Institute. Primary endpoint: Dose limiting toxicity rate at 1 year. Started Jun 2023; status: suspended.
02
Drugs
emavusertib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05685602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685602.